1-(1-phenylcyclohexyl)pyrrolidine: pyrrolidine analog of phencyclidine; RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
rolicyclidine : Pyrrolidine in which the hydrogen attached to the nitrogen is substituted by a 1-phenylcyclohex-1-yl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 62436 |
| CHEMBL ID | 1719398 |
| CHEBI ID | 60805 |
| SCHEMBL ID | 517928 |
| MeSH ID | M0075236 |
| Synonym |
|---|
| CHEBI:60805 , |
| roliciclidina |
| 2201-39-0 |
| rolicyclidinum |
| NCGC00160464-01 |
| DB01549 |
| rolicyclidine |
| 1-(1-phenylcyclohexyl)pyrrolidine |
| pcpy |
| dtxcid6026167 |
| tox21_111832 |
| dtxsid8046167 , |
| cas-2201-39-0 |
| CHEMBL1719398 |
| unii-183o9o9je3 |
| 183o9o9je3 , |
| roliciclidina [inn-spanish] |
| rolicyclidinum [inn-latin] |
| pyrrolidine, 1-(1-phenylcyclohexyl)- |
| hsdb 7636 |
| rolicyclidine [inn] |
| dea no. 7458 |
| rolicyclidine [hsdb] |
| SCHEMBL517928 |
| pyrrolidine, 1-(1-phenylcyclohexyl) |
| 1-(1-phenylcyclohexyl)pyrrolidine (rolicyclidine) |
| FYOWWXMGDATDQY-UHFFFAOYSA-N |
| 1-(1-phenylcyclohexyl)-pyrrolidine |
| Q570183 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Generally, an orderly inverted U-shaped dose-response curve for rates of self-injection has been observed." | ( Animal models of intravenous phencyclinoid self-administration. Marquis, KL; Moreton, JE, 1987) | 0.27 |
| Role | Description |
|---|---|
| hallucinogen | Drugs capable of inducing illusions, hallucinations, delusions, paranoid ideations and other alterations of mood and thinking. |
| NMDA receptor antagonist | Any substance that inhibits the action of N-methyl-D-aspartate (NMDA) receptors. They tend to induce a state known as dissociative anesthesia, marked by catalepsy, amnesia, and analgesia, while side effects can include hallucinations, nightmares, and confusion. Due to their psychotomimetic effects, many NMDA receptor antagonists are used as recreational drugs. |
| general anaesthetic | Substance that produces loss of consciousness. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| tertiary amine | A compound formally derived from ammonia by replacing three hydrogen atoms by hydrocarbyl groups. |
| pyrrolidines | Any of a class of heterocyclic amines having a saturated five-membered ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| USP1 protein, partial | Homo sapiens (human) | Potency | 56.2341 | 0.0316 | 37.5844 | 354.8130 | AID504865 |
| TDP1 protein | Homo sapiens (human) | Potency | 22.7231 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| AR protein | Homo sapiens (human) | Potency | 33.4915 | 0.0002 | 21.2231 | 8,912.5098 | AID743042; AID743054 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 1.5849 | 0.0123 | 7.9835 | 43.2770 | AID1346984 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 26.8325 | 0.0002 | 14.3764 | 60.0339 | AID720692 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 5.0119 | 0.0054 | 28.0263 | 1,258.9301 | AID1346985 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 25.2371 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743075; AID743078 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 15.0890 | 0.0010 | 19.4141 | 70.9645 | AID743094 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 3.1623 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 26.6032 | 0.0007 | 23.0674 | 1,258.9301 | AID743085; AID743122 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 11.8832 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| nuclear receptor subfamily 1, group I, member 2 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 0.1000 | 9.1916 | 31.6228 | AID1346983 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 28.1838 | 0.0178 | 9.6374 | 44.6684 | AID588834 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 14.4393 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 25.5748 | 0.0056 | 12.3677 | 36.1254 | AID624032 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 31.6704 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID720552 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 7 (63.64) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.05) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (7.69%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (7.69%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (84.62%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||